147 related articles for article (PubMed ID: 22541962)
1. Impact of concurrent androgen deprivation on fiducial marker migration in external-beam radiation therapy for prostate cancer.
Tiberi DA; Carrier JF; Beauchemin MC; Nguyen TV; Béliveau-Nadeau D; Taussky D
Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):e7-e12. PubMed ID: 22541962
[TBL] [Abstract][Full Text] [Related]
2. Migration of intraprostatic fiducial markers and its influence on the matching quality in external beam radiation therapy for prostate cancer.
Delouya G; Carrier JF; Béliveau-Nadeau D; Donath D; Taussky D
Radiother Oncol; 2010 Jul; 96(1):43-7. PubMed ID: 20378191
[TBL] [Abstract][Full Text] [Related]
3. Does hormone therapy modify the position of the gold markers in the prostate during irradiation? A daily evaluation with kV-images.
Udrescu C; De Bari B; Rouvière O; Ruffion A; Michel-Amadry G; Jalade P; Devonec M; Colombel M; Chapet O
Cancer Radiother; 2013 Jun; 17(3):215-20. PubMed ID: 23726364
[TBL] [Abstract][Full Text] [Related]
4. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
[TBL] [Abstract][Full Text] [Related]
5. The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer.
Shilkrut M; Merrick GS; McLaughlin PW; Stenmark MH; Abu-Isa E; Vance SM; Sandler HM; Feng FY; Hamstra DA
Cancer; 2013 Feb; 119(3):681-90. PubMed ID: 22893254
[TBL] [Abstract][Full Text] [Related]
6. Intra-prostatic fiducial markers and concurrent androgen deprivation.
Nichol AM; Rosewall T; Catton CN; Jaffray DA; Warde PR
Clin Oncol (R Coll Radiol); 2005 Sep; 17(6):465-8. PubMed ID: 16149291
[TBL] [Abstract][Full Text] [Related]
7. [Evaluation of GoldAnchorTM fiducial marker migration during the planning of radiation treatment for patients with prostate cancer].
Bodusz D; Głowacki G; Leszczyński W; Miśta W; Miszczyk L
Przegl Lek; 2013; 70(1):11-4. PubMed ID: 23789298
[TBL] [Abstract][Full Text] [Related]
8. The impact of androgen deprivation therapy on setup errors during external beam radiation therapy for prostate cancer.
Onal C; Dolek Y; Ozdemir Y
Strahlenther Onkol; 2017 Jun; 193(6):472-482. PubMed ID: 28409246
[TBL] [Abstract][Full Text] [Related]
9. Patient-reported Quality of Life in Patients with Primary Metastatic Prostate Cancer Treated with Androgen Deprivation Therapy with and Without Concurrent Radiation Therapy to the Prostate in a Prospective Randomised Clinical Trial; Data from the HORRAD Trial.
Boevé L; Hulshof MCCM; Verhagen PCMS; Twisk JWR; Witjes WPJ; de Vries P; van Moorselaar RJA; van Andel G; Vis AN
Eur Urol; 2021 Feb; 79(2):188-197. PubMed ID: 32978014
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of gold fiducial marker manual localisation for magnetic resonance-only prostate radiotherapy.
Maspero M; Seevinck PR; Willems NJW; Sikkes GG; de Kogel GJ; de Boer HCJ; van der Voort van Zyp JRN; van den Berg CAT
Radiat Oncol; 2018 Jun; 13(1):105. PubMed ID: 29871656
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of serrated intraprostatic gold coils positional stability using on-board cone beam computed tomography scans acquired throughout the radiation treatment course.
Miceli R; Ingrosso G; Ponti E; di Cristino D; Lancia A; Bove PL; Santoni R
Pract Radiat Oncol; 2015; 5(6):417-22. PubMed ID: 26412339
[TBL] [Abstract][Full Text] [Related]
12. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527
[TBL] [Abstract][Full Text] [Related]
13. Consensus and differences in primary radiotherapy for localized and locally advanced prostate cancer in Switzerland: A survey on patterns of practice.
Panje CM; Dal Pra A; Zilli T; R Zwahlen D; Papachristofilou A; Herrera FG; Matzinger O; Plasswilm L; Putora PM
Strahlenther Onkol; 2015 Oct; 191(10):778-86. PubMed ID: 25986251
[TBL] [Abstract][Full Text] [Related]
14. Interval to biochemical failure predicts clinical outcomes in patients with high-risk prostate cancer treated by combined-modality radiation therapy.
Shilkrut M; McLaughlin PW; Merrick GS; Vainshtein JM; Feng FY; Hamstra DA
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):721-8. PubMed ID: 23664325
[TBL] [Abstract][Full Text] [Related]
15. External-beam radiation therapy and high-dose rate brachytherapy combined with long-term androgen deprivation therapy in high and very high prostate cancer: preliminary data on clinical outcome.
Martínez-Monge R; Moreno M; Ciérvide R; Cambeiro M; Pérez-Gracia JL; Gil-Bazo I; Gaztañaga M; Arbea L; Pascual I; Aristu J
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):e469-76. PubMed ID: 22284039
[TBL] [Abstract][Full Text] [Related]
16. A semi-automated 2D/3D marker-based registration algorithm modelling prostate shrinkage during radiotherapy for prostate cancer.
Budiharto T; Slagmolen P; Hermans J; Maes F; Verstraete J; Heuvel FV; Depuydt T; Oyen R; Haustermans K
Radiother Oncol; 2009 Mar; 90(3):331-6. PubMed ID: 19013658
[TBL] [Abstract][Full Text] [Related]
17. Biochemical response to androgen deprivation therapy before external beam radiation therapy predicts long-term prostate cancer survival outcomes.
Zelefsky MJ; Gomez DR; Polkinghorn WR; Pei X; Kollmeier M
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):529-33. PubMed ID: 23523323
[TBL] [Abstract][Full Text] [Related]
18. The effect of short term neo-adjuvant androgen deprivation on erectile function in patients treated with external beam radiotherapy for localised prostate cancer: an analysis of the 4- versus 8-month randomised trial (Irish Clinical Oncology Research Group 97-01).
Daly PE; Dunne MT; O'Shea CM; Finn MA; Armstrong JG
Radiother Oncol; 2012 Jul; 104(1):96-102. PubMed ID: 22682750
[TBL] [Abstract][Full Text] [Related]
19. Continued benefit to androgen deprivation therapy for prostate cancer patients treated with dose-escalated radiation therapy across multiple definitions of high-risk disease.
Stenmark MH; Blas K; Halverson S; Sandler HM; Feng FY; Hamstra DA
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e335-44. PubMed ID: 21645976
[TBL] [Abstract][Full Text] [Related]
20. External beam radiation therapy and a low-dose-rate brachytherapy boost without or with androgen deprivation therapy for prostate cancer.
Strom TJ; Hutchinson SZ; Shrinath K; Cruz AA; Figura NB; Nethers K; Biagioli MC; Fernandez DC; Heysek RV; Wilder RB
Int Braz J Urol; 2014; 40(4):474-83. PubMed ID: 25251952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
